Elizabeth G Dunne, Cameron N Fick, James M Isbell, Jamie E Chaft, Nasser Altorki, Bernard J Park, Jonathan Spicer, Patrick M Forde, Daniel Gomez, Puneeth Iyengar, David H Harpole, Thomas E Stinchcombe, Moishe Liberman, Matthew J Bott, Prasad S Adusumilli, James Huang, Gaetano Rocco, David R Jones
BACKGROUND: Despite surgical resection, long-term survival of patients with resectable non-small cell lung cancer (NSCLC) remains poor. Adjuvant chemotherapy, the standard of care for locally advanced NSCLC, provides a marginal 5.4% benefit in survival. Immune checkpoint inhibitors (ICIs) have shown a significant survival benefit in some patients with advanced NSCLC and are being evaluated for perioperative use in resectable NSCLC. METHODS: We conducted a literature search using the PubMed online database to identify clinical trials of immunotherapy in resectable NSCLC and studies analyzing biomarkers and immune priming strategies...
February 3, 2024: Annals of Thoracic Surgery